Amit Patel1, Umeer Waheed, Stephen J Brett. 1. Centre for Perioperative Medicine and Critical Care Research, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK. amit.patel@imperial.ac.uk
Abstract
PURPOSE: To assess the impact of 6% tetrastarch [hydroxyethyl starch (HES) 130/0.4 and 130/0.42] in severe sepsis patients. The primary outcome measure was 90-day mortality. METHODS: A structured literature search was undertaken to identify prospective randomised controlled trials (RCTs) in adult patients with severe sepsis receiving 6% tetrastarch (of potato or waxy maize origin) as part of fluid resuscitation in comparison with other non-HES fluids after randomisation in the critical care setting. A systematic review and meta-analysis were performed. RESULTS: Six RCTs were included (n = 3,033): three from 2012 (n = 2,913) had low risk of bias. Median tetrastarch exposure was 37.4 ml/kg (range 30-43 ml/kg). Ninety-day mortality was associated with tetrastarch exposure [relative risk (RR) 1.13; 95% confidence interval (CI) 1.02-1.25; p = 0.02] compared with crystalloid. The number needed to harm (NNH) was 28.8 (95 % CI 14.6-942.5). Publication bias and statistical heterogeneity (I(2) = 0%) were not present. Tetrastarch exposure was also associated with renal replacement therapy (p = 0.01; NNH 15.7) and allogeneic transfusion support (p = 0.001; NNH 9.9). No difference between groups was observed for 28-day mortality, for comparison with colloid as control, or for waxy maize-derived tetrastarch, but power was lacking. Overall mortality was associated with tetrastarch exposure (RR 1.13; 95% CI 1.02-1.25; p = 0.02). CONCLUSIONS: In our analysis, 6% tetrastarch as part of initial fluid resuscitation for severe sepsis was associated with harm and, as alternatives exist, in our view should be avoided.
PURPOSE: To assess the impact of 6% tetrastarch [hydroxyethyl starch (HES) 130/0.4 and 130/0.42] in severe sepsispatients. The primary outcome measure was 90-day mortality. METHODS: A structured literature search was undertaken to identify prospective randomised controlled trials (RCTs) in adult patients with severe sepsis receiving 6% tetrastarch (of potato or waxy maize origin) as part of fluid resuscitation in comparison with other non-HES fluids after randomisation in the critical care setting. A systematic review and meta-analysis were performed. RESULTS: Six RCTs were included (n = 3,033): three from 2012 (n = 2,913) had low risk of bias. Median tetrastarch exposure was 37.4 ml/kg (range 30-43 ml/kg). Ninety-day mortality was associated with tetrastarch exposure [relative risk (RR) 1.13; 95% confidence interval (CI) 1.02-1.25; p = 0.02] compared with crystalloid. The number needed to harm (NNH) was 28.8 (95 % CI 14.6-942.5). Publication bias and statistical heterogeneity (I(2) = 0%) were not present. Tetrastarch exposure was also associated with renal replacement therapy (p = 0.01; NNH 15.7) and allogeneic transfusion support (p = 0.001; NNH 9.9). No difference between groups was observed for 28-day mortality, for comparison with colloid as control, or for waxy maize-derived tetrastarch, but power was lacking. Overall mortality was associated with tetrastarch exposure (RR 1.13; 95% CI 1.02-1.25; p = 0.02). CONCLUSIONS: In our analysis, 6% tetrastarch as part of initial fluid resuscitation for severe sepsis was associated with harm and, as alternatives exist, in our view should be avoided.
Authors: J Cohen; G Guyatt; G R Bernard; T Calandra; D Cook; D Elbourne; J Marshall; A Nunn; S Opal Journal: Crit Care Med Date: 2001-04 Impact factor: 7.598
Authors: John A Myburgh; Simon Finfer; Rinaldo Bellomo; Laurent Billot; Alan Cass; David Gattas; Parisa Glass; Jeffrey Lipman; Bette Liu; Colin McArthur; Shay McGuinness; Dorrilyn Rajbhandari; Colman B Taylor; Steven A R Webb Journal: N Engl J Med Date: 2012-10-17 Impact factor: 91.245
Authors: James A Russell; Keith R Walley; Joel Singer; Anthony C Gordon; Paul C Hébert; D James Cooper; Cheryl L Holmes; Sangeeta Mehta; John T Granton; Michelle M Storms; Deborah J Cook; Jeffrey J Presneill; Dieter Ayers Journal: N Engl J Med Date: 2008-02-28 Impact factor: 91.245
Authors: Simon Finfer; Bette Liu; Colman Taylor; Rinaldo Bellomo; Laurent Billot; Deborah Cook; Bin Du; Colin McArthur; John Myburgh Journal: Crit Care Date: 2010-10-15 Impact factor: 9.097
Authors: Matthias Jacob; Daniel Chappell; Peter Conzen; Mahlon M Wilkes; Bernhard F Becker; Markus Rehm Journal: Crit Care Date: 2008-03-04 Impact factor: 9.097
Authors: B Rochwerg; W Alhazzani; A Gibson; C M Ribic; A Sindi; D Heels-Ansdell; L Thabane; A Fox-Robichaud; L Mbuagbaw; W Szczeklik; F Alshamsi; S Altayyar; W Ip; G Li; M Wang; A Włudarczyk; Q Zhou; D Annane; D J Cook; R Jaeschke; G H Guyatt Journal: Intensive Care Med Date: 2015-04-23 Impact factor: 17.440
Authors: Anders Perner; Nicolai Haase; Per Winkel; Anne B Guttormsen; Jyrki Tenhunen; Gudmundur Klemenzson; Rasmus G Müller; Anders Aneman; Jørn Wetterslev Journal: Intensive Care Med Date: 2014-05-08 Impact factor: 17.440
Authors: Babak Kateby Kashy; Attila Podolyak; Natalya Makarova; Jarrod E Dalton; Daniel I Sessler; Andrea Kurz Journal: Anesthesiology Date: 2014-10 Impact factor: 7.892